NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis $10.85 +0.05 (+0.45%) Closing price 04/17/2025Extended Trading$10.85 0.00 (0.00%) As of 04/17/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enfusion Stock (NYSE:ENFN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enfusion alerts:Sign Up Key Stats Today's Range$10.74▼$10.8750-Day Range$10.47▼$11.1852-Week Range$7.83▼$11.80Volume2.46 million shsAverage Volume662,526 shsMarket Capitalization$1.40 billionP/E Ratio271.29Dividend YieldN/APrice Target$12.25Consensus RatingHold Company OverviewEnfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.Read More… Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Stock News HeadlinesClearwater Analytics reinstated with an Overweight at JPMorganApril 26, 2025 | markets.businessinsider.comClearwater Analytics: 3 Acquisitions That Make This A Strong BuyApril 24, 2025 | seekingalpha.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 21, 2025 | Stansberry Research (Ad)Clearwater Analytics Finalizes Acquisition of EnfusionApril 21, 2025 | businesswire.comClearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger ConsiderationApril 2, 2025 | businesswire.comENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFNApril 2, 2025 | businesswire.comEnfusion, Inc.: Enfusion Announces Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | finanznachrichten.deEnfusion Announces Fourth Quarter and Full Year 2024 ResultsMarch 3, 2025 | businesswire.comSee More Headlines ENFN Stock Analysis - Frequently Asked Questions How have ENFN shares performed this year? Enfusion's stock was trading at $10.30 at the beginning of 2025. Since then, ENFN stock has increased by 5.3% and is now trading at $10.8490. View the best growth stocks for 2025 here. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) posted its earnings results on Monday, March, 3rd. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.02. The firm had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a net margin of 1.70% and a trailing twelve-month return on equity of 6.67%. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's top institutional shareholders include Vanguard Group Inc. (2.77%), Alpine Associates Management Inc. (1.89%), Trium Capital LLP (1.35%) and Nexpoint Asset Management L.P. (0.68%). Insiders that own company stock include Neal Pawar, Oleg Movchan, Bradley Herring, Bronwen Bastone, Dan Groman, Matthew Campobasso, Valeria Gutowski, Deirdre Somers, Tarek Hammoud and Stephen Malherbe. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enfusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enfusion investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings3/03/2025Today5/21/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryComputer Software Current SymbolNYSE:ENFN CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$13.00 Low Stock Price Target$11.50 Potential Upside/Downside+12.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio271.29 Forward P/E Ratio180.82 P/E Growth1.85Net Income$6.03 million Net Margins1.70% Pretax Margin3.64% Return on Equity6.67% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$201.61 million Price / Sales6.94 Cash Flow$0.14 per share Price / Cash Flow78.75 Book Value$0.61 per share Price / Book17.79Miscellaneous Outstanding Shares129,001,000Free Float81,720,000Market Cap$1.40 billion OptionableOptionable Beta0.92 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NYSE:ENFN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.